Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Erick Campbell"'
Autor:
Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell, Amber M Johnson, Sarina A. Piha-Paul, Isabella C. Glitza Oliva, Shiao-Pei Weathers, Maria Cabanillas, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-11 (2024)
Abstract Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rechallenged with a second RAF in
Externí odkaz:
https://doaj.org/article/536748e4fa9d4e778632dfc29b4e5ed7
Autor:
Shuyang Yao, Funda Meric-Bernstam, David Hong, Filip Janku, Aung Naing, Sarina Anne Piha-Paul, Apostolia Maria Tsimberidou, Daniel Karp, Vivek Subbiah, Timothy Anthony Yap, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Chetna Wathoo, Erick Campbell, Lihou Yu, Yuko Yamamura, Siqing Fu
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therape
Externí odkaz:
https://doaj.org/article/a5b386ae4dfe4117b0a471663d796ae6
Autor:
Pavlos Msaouel, Nizar M. Tannir, Eric Jonasch, Hung Le, Andrew W Hahn, Omar Alhalabi, Erick Campbell
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Background For patients with metastatic renal cell carcinoma (mRCC) who progress on standard-of-care therapies, there is an unmet need for novel treatments. Phase I clinical trials are designed to test the safety, toxicity and optimal dosing of novel
Externí odkaz:
https://doaj.org/article/ef5fcfa477fa46b6a2d537bc3561c46a
Autor:
Fedricker D, Barber, Erick, Campbell, Yuko, Yamamura, Clover J, Patterson, Audrey C, Hartnett, Holly, Kinahan, Victoria A, Miller, Amanda L, Brink, Anna, Poullard, Gabriele E, Urschel, Andre, Brantley, Isabel G, Cepeda, Poonam, Goswami, Sheena, Charles, Shincy, Philip, Sara, Bresser, Sandra, Musekiwa-Adjei, Nageli, Perez, Hung, Le, Penny, Phillips, Vivek, Subbiah, Funda, Meric-Bernstam, Ecaterina E, Dumbrava
Publikováno v:
Journal of the Advanced Practitioner in Oncology. 13:664-672
Background: Advanced practice providers (APPs) play important roles in enrolling, educating, and caring for patients in clinical trials. However, much remains unknown about the role of APPs in managing adverse events (AEs) in early (phase I to II) cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a98b5c8ce78d6fcff7904bf21788a93
https://doi.org/10.6004/jadpro.2022.13.7.2
https://doi.org/10.6004/jadpro.2022.13.7.2
Autor:
Blessie Elizabeth Nelson, Chinenye Lynette Ejezie, Bettzy A. Stephen, Mirella Nardo, Erick Campbell, Jing Gong, David S. Hong, Siqing Fu, Timothy A. Yap, Mariela Blum Murphy, Sarina Piha-Paul, Naval G. Daver, Cristhiam M. Rojas-Hernandez, Aung Naing
Publikováno v:
Journal of Hematology. 11:113-120
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e823d583ded7297eb50ab86c9343b695
https://doi.org/10.14740/jh1006
https://doi.org/10.14740/jh1006
Autor:
Filip Janku, Matthew T. Campbell, Siqing Fu, Funda Meric-Bernstam, Timothy A. Yap, Andrew W. Hahn, Arlene O. Siefker-Radtke, Hung Le, Sarina Anne Piha-Paul, Vivek Subbiah, Nathaniel R. Wilson, Omar Alhalabi, Nizar M. Tannir, Kimberly Beltran, David S. Hong, Shubham Pant, Erick Campbell, Jianjun Gao, Janos Roszik, Pavlos Msaouel, Amishi Yogesh Shah, Aung Naing, Daniel D. Karp
Publikováno v:
Clinical Genitourinary Cancer. 20:e16-e24
Introduction Enrolling patients with metastatic urothelial carcinoma (mUC) in phase I trials provides an opportunity to identify biological drug activity. Developing prognostic scores may aid in patient selection for phase 1 trials. Patients and Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::495f4f80106bb3f8f0cc680499ac82f3
https://doi.org/10.1016/j.clgc.2021.07.004
https://doi.org/10.1016/j.clgc.2021.07.004
Autor:
Amishi Yogesh Shah, Pavlos Msaouel, Siqing Fu, Hung Le, Timothy A. Yap, Vivek Subbiah, Sarina Anne Piha-Paul, Janku Filip, David S. Hong, Funda Meric-Bernstam, Erick Campbell, Alexander Y. Andreev-Drakhlin, Aung Naing, Matthew T. Campbell, Daniel D. Karp, Shubham Pant, Jianjun Gao, Jason Roszik, Arlene O. Siefker-Radtke, Andrew W. Hahn, Omar Alhalabi, Nizar M. Tannir
Publikováno v:
Molecular Cancer Research. 19:395-402
Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies. We retrospectively analyzed medical records of 43 patients with platinum-refractory metastatic bladder cancer (mBC) who participated in one
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cba3942736e5fbe8d3bdb1ca4eb8d845
https://doi.org/10.1158/1541-7786.mcr-20-0751
https://doi.org/10.1158/1541-7786.mcr-20-0751
Autor:
Natalie Y. Ngoi, Heather Y. Lin, Ecaterina Dumbrava, Siqing Fu, Daniel D. Karp, Aung Naing, Shubham Pant, Sarina A. Piha-Paul, Jordi Rodon, Vivek Subbiah, Apostolia M. Tsimberidou, Erick Campbell, Samuel Urrutia, David S. Hong, Funda Meric-Bernstam, Ying Yuan, Timothy A. Yap
Publikováno v:
Cancer Research. 83:6181-6181
Introduction: Clinical trials are exploring ATR inhibitors (ATRi) in genomically selected contexts. However, dose-dependent anemia has limited the therapeutic index of this class. We hypothesized that monocytes and reticulocytes are more vulnerable t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ff2ad31f9cb8457d3ed6a9f3e62d273
https://doi.org/10.1158/1538-7445.am2023-6181
https://doi.org/10.1158/1538-7445.am2023-6181
Autor:
Patrick G. Pilie, Daniel Mcgrail, Wei-Lien Wang, Natalie Ngoi, Keith Kyewalabye, Khalida Wani, Hung Le, Erick Campbell, Vijaykumar Holla, Kenna R. Shaw, Funda Meric-Bernstam, Alexander J. Lazar, Virginia Giuliani, Timothy Heffernan, Timothy A. Yap
Publikováno v:
Cancer Research. 83:3432-3432
Introduction: ATM loss of function (LOF) in cancer may serve as a predictive biomarker of response for antitumor therapies. However, clinical studies of targeted treatments in ATM-aberrant patients have yielded mixed results; thus, identifying the op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dd8e485f40f348d2f0980a1d3c861f3
https://doi.org/10.1158/1538-7445.am2023-3432
https://doi.org/10.1158/1538-7445.am2023-3432
Autor:
Shuyang Yao, Funda Meric-Bernstam, David Hong, Filip Janku, Aung Naing, Sarina Anne Piha-Paul, Apostolia Maria Tsimberidou, Daniel Karp, Vivek Subbiah, Timothy Anthony Yap, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Chetna Wathoo, Erick Campbell, Lihou Yu, Yuko Yamamura, Siqing Fu
Publikováno v:
Scientific reports. 12(1)
Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044f834bbce4a3136b7444d4a47af669
https://pubmed.ncbi.nlm.nih.gov/35610322
https://pubmed.ncbi.nlm.nih.gov/35610322